Physician profile
Jonathan Michael Davis
NPI 1053738336
$16,273.67
in general payments reported to CMS, 2019-2025
23 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.91 · 2021: $122 · 2022: $189 · 2023: $525 · 2024: $13K · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,045 · Travel and Lodging: $4,168 · Food and Beverage: $3,727 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,045.45 |
| Travel and Lodging | $4,168.38 |
| Food and Beverage | $3,726.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,299.98 | 2024-2025 | |
| Pulmonx Corporation | $1,272.73 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $609.91 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $449.45 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Actelion Pharmaceuticals US, INC. | $254.44 | 2019-2022 | |
| Olympus America INC. | $231.70 | 2025 | Spiration Valve System |
| Genzyme Corporation | $166.05 | 2025 | |
| Davol INC. | $149.41 | 2025 | Progel Applicator Spray Tips |
| Medtronic, INC. | $133.21 | 2023 | Illumisite |
| Abbvie INC. | $103.35 | 2024-2025 | |
| Baxter Healthcare | $96.34 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Metaneb System, Hillrom - Life 2000 Ventilation System |
| Mylan Specialty L.P. | $96.11 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $57.04 | 2024-2025 | Glassia |
| Erbe USA INC | $50.00 | 2025 | Cryo2 |
| Insmed, INC. | $49.65 | 2024-2025 | Brinsupri, Arikayce |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.60 | 2023 | |
| Viatris Specialty LLC | $42.15 | 2025 | Yupelri |
| United Therapeutics Corporation | $41.07 | 2025 | Tyvaso |
| Merck Sharp & Dohme LLC | $35.83 | 2024-2025 | Winrevair |
| Edwards Lifesciences Corporation | $28.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.41 | 2025 | Ofev |
| Verona Pharma, INC. | $22.12 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.